Indacaterol/glycopyrronium (IND/GLY) 110/50 mcg was the first once-daily, long-acting β₂-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). Development of IND/GLY was driven by the need to improve the standard of care for patients with this disease, in terms of symptom control and exacerbation frequency. IGNITE, an adaptive, comprehensive, and innovative Phase 3 development program, demonstrated the efficacy of IND/GLY in optimising bronchodilation, reducing symptoms, and reducing exacerbations in patients with COPD. IGNITE challenged contemporary thinking about the pharmacological treatment and management of patients with this disease.

茚达特罗/格隆（IND / GLY）五十〇分之一百一微克是第一每日一次，长效β ₂批准在欧洲为激动剂（LABA）/长效毒蕈碱拮抗剂（LAMA）固定剂量组合（FDC）慢性阻塞性肺疾病（COPD）的治疗。IND / GLY的发展是由在症状控制和加重发作频率方面提高对这种疾病患者的护理标准的需求所驱动的。IGNITE是一项具有适应性，全面且创新的3期开发计划，它证明了IND / GLY在优化COPD患者的支气管扩张，减轻症状和减轻病情恶化方面的功效。IGNITE挑战了有关这种疾病患者的药物治疗和管理的当代思想。